Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells

BMC Biochemistry

Volumn 14, Issue 1, 2013, Pages

  Massai, Luisa ^a   Petricca, Lara ^a   Magnoni, Letizia ^a   Rovetini, Luca ^a   Haider, Salman ^b   Andre, Ralph ^b   Tabrizi, Sarah J ^b   Süssmuth, Sigurd D ^c   Landwehrmeyer, Bernhard G ^c   Caricasole, Andrea ^a   Pollio, Giuseppe ^a   Bernocco, Simonetta ^a  

^a Siena Biotech SpA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; HUNTINGTIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MAMMAL CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; RAT; SENSITIVITY ANALYSIS; WILD TYPE;

MAMMALIA;

ANTIBODIES; BLOOD CHEMICAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; LEUKOCYTES, MONONUCLEAR; MASS SPECTROMETRY; MUTATION; NERVE TISSUE PROTEINS; QUALITY CONTROL; RECOMBINANT PROTEINS;

EID: 84888098438     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-14-34     Document Type: Article

References (50)

1. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, Nat Genet 1993 4 398 403 10.1038/ng0893-398 8401589 (Pubitemid 23231490)
2. Mechanisms of neurodegeneration in Huntington's disease. Gil JM, Rego AC, Euro J Neurosci 2008 27 2803 2820 10.1111/j.1460-9568.2008.06310.x (Pubitemid 351832229)
3. Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. Sathasivam K, Amaechi I, Mangiarini L, Bates G, Hum Genet 1997 5 692 695 (Pubitemid 27192608)
4. Single step scalable-throughput molecular screening for Huntington disease. Teo CRL, Wang W, Law HY, Lee CG, Chong SS, Clin Chem 2008 54 964 972 10.1373/clinchem.2007.096503 18403567 (Pubitemid 351793402)
5. Triplet repeat primed PCR simplifies testing for Huntington disease. Jama M, Millson A, Miller CE, Lyon E, J Mol Diagn 2013 15 255 262 10.1016/j.jmoldx.2012.09.005 23414820
6. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R, Hum Mol Genet 2007 16 2600 2615 10.1093/hmg/ddm217 17704510 (Pubitemid 47617727)
7. Protein aggregates in Huntington's disease. Arrasate M, Finkbeiner S, Exp Neurol 2012 238 1 11 10.1016/j.expneurol.2011.12.013 22200539
8. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Browne SE, Ann NY Acad Sci 2008 1147 358 382 10.1196/annals.1427.018 19076457
9. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. Jin YN, Yu YV, Gundemir S, Jo C, Cui M, Tieu K, Johnson GV, Plos One 2013 8 3 57932 10.1371/journal.pone.0057932 23469253
10. Huntingtin modulates transcription, occupies gene promoters in vivo, binds directly to DNA in a polyglutamine-dependent manner. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, Clark TW, Bouzou B, Cha JH, J Neurosci 2008 28 10720 10733 10.1523/JNEUROSCI.2126-08.2008 18923047
11. Huntington's disease: degradation of mutant huntingtin by autophagy. Sarkar S, Rubinsztein DC, FEBS J 2008 275 17 4263 4270 10.1111/j.1742-4658.2008. 06562.x 18637946
12. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC, Cell Death Differ 2009 16 46 56 10.1038/cdd.2008.110 18636076
13. Cholesterol metabolism in Huntington disease. Karasinska JM, Hayden MR, Nat Rev Neurol 2011 7 561 572 10.1038/nrneurol.2011.132 21894212
14. Loss of normal huntingtin function: new developments in Huntington's disease research. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S, Trends Neurosci 2001 24 182 188 10.1016/S0166-2236(00)01721-5 11182459 (Pubitemid 32166824)
15. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR, BMC Neurosci 2006 7 80 10.1186/1471-2202-7-80 17147801 (Pubitemid 46178874)
16. Wild-type huntingtin protects from apoptosis upstream of caspase-3. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E, J Neurosci 2000 20 10 3705 3713 10804212 (Pubitemid 30266233)
17. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Underwood B, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC, Brain 2006 129 877 886 10.1093/brain/awl027 16464959
18. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ, Hum Mol Genet 2010 19 20 3919 3935 10.1093/hmg/ddq306 20660112
19. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR, Hum Mol Genet 2010 199 8 1438 1452
20. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Aziz NA, Jurgens CK, Landwehrmeyer GB, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA, Orth M, Handley OJ, Schwenke C, Ho A, Wild EJ, Tabrizi SJ, Landwehrmeyer GB, Neurology 2009 73 1280 1285 10.1212/WNL.0b013e3181bd1121 19776381
21. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili- Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Moller T, Tabrizi SJ, J Exp Med 2008 205 1869 1877 10.1084/jem.20080178 18625748
22. Genetic and environmental factors in the pathogenesis of Huntington's disease. Van Dellen A, Hannan AJ, Neurogenetics 2004 5 1 9 17 10.1007/s10048-003-0169-5 14745585 (Pubitemid 38297468)
23. Differential loss of striatal projection neurons in Huntington disease. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB, Proc Natl Acad Sci USA 1988 85 5733 5737 10.1073/pnas.85.15.5733 2456581
24. Widespread expression of the human and rat Huntington's disease gene in brain and nonneuronal tissues. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz K, Collins FS, Albin RL, Nat Genet 1993 5 259 265 10.1038/ng1193-259 8275091 (Pubitemid 23330389)
25. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Landwehrmeyer GB, McNeil SM, Dure LS, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, Ann Neurol 1995 37 218 230 10.1002/ana.410370213 7847863
26. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Zuccato C, Valenza M, Cattaneo E, Physiol Rev 2010 90 905 981 10.1152/physrev.00041.2009 20664076
27. Formation of polyglutamine inclusions in non-CNS tissue. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP, Hum Mol Genet 1999 8 5 813 822 10.1093/hmg/8.5.813 10196370 (Pubitemid 29189048)
28. A phenotypic screening assay for modulators of Huntingtin-induced transcriptional dysregulation. Lazzeroni G, Benicchi T, Heitz F, Magnoni L, Diamanti D, Rossini L, Massai L, Federico C, Fecke W, Caricasole A, La Rosa S, Porcari V, J Biomol Screen in press
29. A screen for enhancers of clearance identifies huntingtin asa heat shock protein 9 (Hsp90) client protein. Baldo B, Weiss A, Parker CN, Bibel M, Paganetti P, Kaupmann K, JBC 2011 287 1406 1414
30. 4,5-diarylisoxazole HSP90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L, J Med Chem 2008 51 2 196 218 10.1021/jm701018h 18020435
31. Acetylation targets mutant huntingtin to autophagosomes for degradation. Jeong H, Then F, Melia TJ Jr, Mazzulli JR, Cui L, Savas JN, Voisine C, Paganetti P, Tanese N, Hart AC, Yamamoto A, Krainc D, Cell 2009 137 60 72 10.1016/j.cell.2009.03.018 19345187
32. Huntington's disease: tagged for clearance. Krainc D, Nat Med 2010 16 1 32 3 10.1038/nm0110-32 20057421
33. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. HD Collaborative Research Group, Cell 1993 72 971 983 10.1016/0092-8674(93)90585-E 8458085 (Pubitemid 23110238)
34. Huntington's disease: progress and potential in the field. Stack EC, Ferrante RJ, Expert Opin Investig Drugs 2007 16 1933 1953 10.1517/13543784.16. 12.1933 18042002 (Pubitemid 351403725)
35. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson LM, Marsh JL, Proc Natl Acad Sci USA 2005 102 3777 3781 10.1073/pnas.0500055102 15716359 (Pubitemid 40354688)
36. Pharmacologic approaches to the treatment of Huntington's disease. Venuto CS, McGarry A, Ma Q, Kieburtz K, Mov Disord 2012 27 1 31 41 10.1002/mds.23953 21997232
37. Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. Li W, Serpell LC, Carter WJ, Rubinsztein DC, Huntington JA, Biol Chem 2006 281 23 15916 22 10.1074/jbc.M511007200 (Pubitemid 43848484)
38. Huntington's disease. Finkbeiner S, Cold Spring Harb Perspect Biol 2011 3 6 007476 21441583
39. A compact β model of huntingtin toxicity. Zhang QC, Yeh TL, Leyva A, Frank LG, Miller J, Kim YE, Langen R, Finkbeiner S, Amzel ML, Ross CA, Poirier MA, J Biol Chem 2011 286 10 8188 8196 10.1074/jbc.M110.192013 21209075
40. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, Osmand A, Gray M, Thulasiramin V, Saudou F, Segal M, Yang XW, Masliah E, Thompson LM, Muchowski PJ, Weisgraber KH, Finkbeiner S, Nat Chem Biol 2011 7 12 925 934 10.1038/nchembio.694 22037470
41. Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death. Juenemann K, Weisse C, Reichmann D, Kaether C, Calkhoven CF, Schilling G, Neurotox Res 2011 20 120 133 10.1007/s12640-010-9227- 6 21116768
42. Native mutant huntingtin in human brain: evidence for prevalence of full length monomer. Sapp E, Valencia A, Li X, Aronin N, Kegel KB, Vonsattel JP, Young NB, Wexler N, DiFiglia M, JBC 2012 287 16 13487 99 10.1074/jbc.M111.286609
43. A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, Nguyen HPJ, J Neurosci 2012 32 44 15426 38 10.1523/JNEUROSCI.1148-12.2012 23115180
44. Full length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW, J Neurosci 2008 28 24 6182 6195 10.1523/JNEUROSCI.0857-08.2008 18550760
45. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW, Neuron 2009 64 6 828 840 10.1016/j.neuron.2009.11.020 20064390
46. Genetic suppression of neurodegeneration and neurotransmitter release abnormalities caused by expanded full-length huntingtin accumulating in the cytoplasm. Romero E, Cha GH, Verstreken P, Ly CV, Hughes RE, Bellen HJ, Botas J, Neuron 2008 57 1 27 40 10.1016/j.neuron.2007.11.025 18184562
47. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease. Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC, Semmelroth M, Zivanovic A, Abramowski D, Smith D, Lotz GP, Bates GP, Weiss A, Chem Biol 2012 19 264 275 10.1016/j.chembiol.2011.12.020 22365609
48. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, Fox J, Kegel K, Klein C, Grueninger S, Hersch S, Housman D, Régulier E, Rosas HD, Stefani M, Zeitlin S, Bilbe G, Paganetti P, Anal Biochem 2009 395 8 15 10.1016/j.ab.2009.08.001 19664996
49. Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. Weiss A, Grueninger S, Abramowski D, Di Giorgio FP, Moscovitch Lopatin M, Rosas HD, Hersch S, Paganetti P, Anal Biochem 2011 410 304 306 10.1016/j.ab.2010.11.044 21134349
50. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ, J Clin Invest 2012 122 3731 3736 10.1172/JCI64565 22996692